Rimegepant plus immunotherapy for colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding rimegepant (a migraine drug) to a PD-1 inhibitor (a type of immunotherapy) can help patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can slow down the cancer or shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced colorectal cancer that cannot be fully removed with surgery.
- Your cancer must have gotten worse after at least one standard treatment, or you couldn't tolerate it.
- You must have at least one tumor that can be measured on a scan (RECIST criteria).
- You must be in good enough health to perform daily activities (ECOG 0-1) and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—everolimus, which may slow cancer growth, and a PD-1 inhibitor, which helps the immune system fight cancer—for people with advanced colorectal cancer that has progressed after standard treatments. The goal is to see if the combination can shrink or control the cancer.
This trial tests a combination therapy that includes an immunotherapy drug (called anti-PD-1) for people with rectal cancer that has spread to the liver or lungs. The goal is to see if this treatment can help shrink or control the cancer, and it may be an option if you haven't had treatment yet.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This study tests a new combination of two drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to standard treatments. The goal is to see if this combination is safe and can help shrink or control the cancer.
This trial tests a combination of two extra drugs (pirfenidone and sintilimab) added to standard chemotherapy before surgery. The goal is to see if this combination can help shrink or control colorectal cancer that has spread to the lining of the abdomen.
This study tests a combination of three treatments—pirfenidone (an anti-scarring drug), a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), and sometimes radiation—for colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can slow or shrink your cancer.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.